Importantly, this hypothesis is consistent with findings in gene expression studies performed on specific clinicopathological (smoking) or mutation subgroups (EGFR/KRAS) in lung adenocarcinoma [41, 46, 47]. The gene discussed is EGFR; the disease is lung adenocarcinoma.